Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease (phase II, n=61), ORR 49% (95% CI 36–62) in VHL-associated renal cell carcinoma; ORR 63% in hemangioblastomas and pancreatic neuroendocrine tumors, duration of response >12 months for >50% of patients [33]. This evidence concerns the gene VHL and von Hippel-Lindau disease.